Low frequency of SARS-CoV-2 3CL protease resistance mutations after nirmatrelvir/ritonavir in immunocompromised patients with persistent infection: a single-centre genomic study in Japan
Nirmatrelvir/ritonavir shows low resistance in immunocompromised patients with persistent SARS-CoV-2.